New light therapy for intermediate age-related macular degeneration
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital, Hormones & metabolism, Injuries & trauma clinical trials.
This trial tests a new light-based treatment for intermediate age-related macular degeneration (AMD), a common eye condition that can lead to vision loss. The goal is to see if it is safe and helps slow down the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years old or older
- You have intermediate AMD (Grade AREDS 3)
- Both of your eyes can be treated in this study
- You are willing to follow the study rules and come for follow-up visits
- You will keep your current diet and lifestyle habits as much as possible during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new laser treatment (MacuTherm) for intermediate age-related macular degeneration (iAMD), an eye condition that affects central vision. The study aims to see if this treatment can slow or prevent progression to more advanced stages of the disease.
This trial tests a new type of electrical stimulation, called microcurrent therapy, to see if it can help people with a certain form of age-related macular degeneration (AMD) that is not the "wet" kind. The treatment is delivered through an eye patch-like device and may slow vision loss or improve function.
This study tests whether a special low-level laser treatment (photobiomodulation) can help people with an early form of age-related macular degeneration called reticular pseudodrusen. It may slow vision loss or protect your eyes from getting worse.
This study tests whether low-level red-light therapy can help people with dry age-related macular degeneration (AMD), a common cause of vision loss in older adults. The therapy is a painless light treatment that you might receive in multiple sessions, and the study aims to see if it can slow or improve vision decline.
This study is testing whether shining a special light on the eye, called photobiomodulation, can help people with dry age-related macular degeneration (AMD). If you have dry AMD and are willing to participate, you will receive the light treatment and be monitored.
This trial tests a new way to deliver lutein, a nutrient that may help with eye health, directly into the eye using a mild electrical current (called iontophoresis). It is for people with intermediate age-related macular degeneration (AMD), a common cause of vision loss in older adults.
Hear when a new Intermediate AMD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.